Compare · CHNG vs CLBS
CHNG vs CLBS
Side-by-side comparison of Change Healthcare Inc. (CHNG) and Caladrius Biosciences Inc. (CLBS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CHNG and CLBS operate in Managed Health Care (Health Care), so they compete in similar markets.
- CHNG is the larger of the two at $6.09B, about 139.5x CLBS ($43.6M).
- CHNG has more recent analyst coverage (5 ratings vs 0 for CLBS).
- Company
- Change Healthcare Inc.
- Caladrius Biosciences Inc.
- Price
- $27.49+0.24%
- $6.45+1176.72%
- Market cap
- $6.09B
- $43.6M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Managed Health Care
- Managed Health Care
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 0
- 0
- Recent ratings
- 5
- 0
Change Healthcare Inc.
Change Healthcare Inc., an independent healthcare technology company, provides data and analytics-driven solutions to enhance clinical, financial, administrative, and patient engagement outcomes in the United States healthcare system. It operates through three segments: Software and Analytics, Network Solutions, and Technology-Enabled Services. The Software and Analytics segment offers software and analytics solutions for revenue cycle management, provider network management, payment accuracy, clinical decision support, value-based payment, consumer engagement, risk adjustment and quality performance, and imaging and clinical workflow. The Network Solutions segment provides solutions for financial, administrative, and clinical and pharmacy transactions; connected consumer health; intelligent healthcare network; electronic business-to-business and consumer-to-business payments; data; and aggregation and analytics of clinical and financial data. The Technology-Enabled Services segment offers solutions for financial and administrative management, value-based care, communication and payment, pharmacy benefits administration, and healthcare consulting. The company serves commercial insurers, private insurers, BlueCross Blue Shield plans, Medicare/Medicaid plans, provider-sponsored payers, third party administrators, emerging technology and data-driven health plans, and other specialty health benefits insurers, as well as hospitals and health systems, physician practices, dentists, pharmacies, skilled nursing facilities, home health agencies, telehealth providers, senior care facilities, laboratories, and other healthcare providers. Change Healthcare Inc. was incorporated in 2016 and is headquartered in Nashville, Tennessee.
Caladrius Biosciences Inc.
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; OLOGO, a regenerative medicine advanced therapy for treating no-option refractory disabling angina; CLBS16 that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Latest CHNG
- SEC Form SC 13G/A filed by Change Healthcare Inc. (Amendment)
- SEC Form 15-12G filed by Change Healthcare Inc.
- SEC Form SC 13D filed by Change Healthcare Inc.
- SEC Form 4: Rareshide Paul was granted 9,177 shares and returned $302,073 worth of shares to the company (49,968 units at $6.05), closing all direct ownership in the company
- SEC Form 4: Domenici Nella returned 29,280 shares to the company, closing all direct ownership in the company
- SEC Form 4: De Crescenzo Neil E. returned $15,274,411 worth of shares to the company (1,557,392 units at $9.81) and was granted 220,264 shares, closing all direct ownership in the company
- SEC Form 4: Laur Thomas was granted 45,888 shares and returned $1,808,577 worth of shares to the company (264,489 units at $6.84), closing all direct ownership in the company
- SEC Form 4: Pead Philip M returned $1,594,852 worth of shares to the company (102,642 units at $15.54), closing all direct ownership in the company
- SEC Form 4: Joshi Kriten returned $5,569,236 worth of shares to the company (569,000 units at $9.79) and was granted 45,888 shares, closing all direct ownership in the company
- SEC Form 4: Mckenzie Diana returned 40,706 shares to the company, closing all direct ownership in the company
Latest CLBS
- SEC Form 4: Mazzo David J covered exercise/tax liability with 397 shares, decreasing direct ownership by 0.41% to 96,543 units
- SEC Form 4: Mazzo David J covered exercise/tax liability with 1,030 shares, decreasing direct ownership by 1% to 96,940 units
- SEC Form 4: Ruoslahti Erkki was granted 20,000 shares
- SEC Form 4: Klosk Steven M was granted 20,000 shares, increasing direct ownership by 198% to 30,090 units
- SEC Form 4: Henson Heidi was granted 20,000 shares
- SEC Form 4: Flowers Cynthia Louise was granted 20,000 shares, increasing direct ownership by 206% to 29,721 units
- SEC Form 4: Brown Gregory B was granted 20,000 shares, increasing direct ownership by 201% to 29,934 units
- SEC Form 4: Azab Mohammad was granted 20,000 shares, increasing direct ownership by 104% to 39,200 units
- SEC Form 4: Slack David W. was granted 24,000 shares and covered exercise/tax liability with 3,358 shares
- SEC Form 4: Mazzo David J was granted 60,000 shares and covered exercise/tax liability with 11,315 shares, increasing direct ownership by 99% to 97,970 units